1541 fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
ImmuneOnco Biopharmaceuticals (Shanghai), Inc. operates as an early-stage biopharmaceutical company which develops and commercializes novel cancer immunotherapeutic products. It focus on the adaptive immune system and are often confronted with limited clinical benefits due to low response rates and inevitable drug resistance and/or relapse in many cancer indications. The company was founded by Dr. Tian Wenzhi in June 2015 and is headquartered in Zhangjiang Science City, China.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
No dividends
1541 has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company